Literature DB >> 11568737

Treatment of psoriasis. Part 1. Topical therapy and phototherapy.

M Lebwohl1, S Ali.   

Abstract

UNLABELLED: New developments in the topical therapy and phototherapy of psoriasis have greatly improved our ability to safely and effectively treat this debilitating disease. Topical corticosteroids remain the most commonly prescribed agents for psoriasis, but they are frequently prescribed with other agents. Investigations of corticosteroids claiming an improved benefit/risk ratio have yielded promising results, but more work is needed. Use of anthralin and tar has declined with the availability of the noncorticosteroids calcipotriene and tazarotene. Other experimental topical therapies are in various stages of development. Broadband ultraviolet B (UVB) remains the most commonly used phototherapy light source, but many patients are being treated with a new form of ultraviolet light, narrowband UVB. Although PUVA remains one of the most effective psoriasis treatments, its use is declining because of its association with cutaneous malignancies. New radiation sources such as lasers have been added to our armamentarium of available therapies and even newer light source-based treatments are being examined. LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should be familiar with the varying topical treatments for psoriasis as well as the different modalities of phototherapy. Participants should also have a better understanding of side effects associated with each treatment, which should help in determining options for therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568737     DOI: 10.1067/mjd.2001.117046

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

1.  The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

2.  Dermacase. Psoriasis.

Authors:  Irina Turchin; Stewart P Adams
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 3.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Cost-effectiveness of treatment with etanercept for psoriasis in Sweden.

Authors:  Christopher Knight; Josephine Mauskopf; Mats Ekelund; Amitabh Singh; Shiyi Yang; Robert Boggs
Journal:  Eur J Health Econ       Date:  2011-03-06

Review 5.  Topical therapies for psoriasis: evidence-based review.

Authors:  Tarek Afifi; Gillian de Gannes; Changzheng Huang; Youwen Zhou
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

Review 6.  Psoriasis treatment: traditional therapy.

Authors:  M Lebwohl; P T Ting; J Y M Koo
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

7.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

8.  1,4-dihydroxy-2-naphthoic Acid Induces Apoptosis in Human Keratinocyte: Potential Application for Psoriasis Treatment.

Authors:  Chong-Fai Mok; Chuan-Ming Xie; Kathy Wai-Yan Sham; Zhi-Xiu Lin; Christopher Hon-Ki Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-11       Impact factor: 2.629

9.  Antipsoriatic activity and cytotoxicity of ethanolic extract of Nigella sativa seeds.

Authors:  Lalitha Priyanka Dwarampudi; Dhanabal Palaniswamy; Muruganantham Nithyanantham; P S Raghu
Journal:  Pharmacogn Mag       Date:  2012-10       Impact factor: 1.085

10.  Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).

Authors:  Kristian Reich; Ulrich Mrowietz; Eleni Karakasili; Ina Zschocke
Journal:  Arch Dermatol Res       Date:  2014-06-04       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.